Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists - Top-Institutions - MDSpire

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

  • By

  • Yuanli Li

  • Changxin Chen

  • Chengdang Wang

  • April 27, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #2

    Mount Sinai Hospital - Icahn School of Medicine
    Mount Sinai Hospital - Icahn School of Medicine

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Translational Research

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

Original Source(s)

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

  • by Yuanli Li, Changxin Chen, Chengdang Wang

  • April 27, 2026

Related Content

Renal Conditions Associated with Inflammatory Bowel Disease: Exploring Clinical Links, Shared Mechanisms, and Management Approaches

Strategies for Organ Regeneration Using Cell Therapy

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management